LCOH, Département de Chimie, Faculté des Sciences, Université Mohamed V, BP1014, Rabat 10100, Morocco.
Laboratory of Pharmacology and Toxicology, Pharmacokinetic Research Team, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco.
J Inorg Biochem. 2019 Feb;191:21-28. doi: 10.1016/j.jinorgbio.2018.11.006. Epub 2018 Nov 9.
In the present study, two pyrazole-acetamide derivatives namely N‑(2‑aminophenyl)‑2‑(5‑methyl‑1H‑pyrazol‑3‑yl) acetamide (L1) and (E)‑N‑(2‑(1‑(2‑hydroxy‑6‑methyl‑4‑oxo‑4H‑pyran‑3‑yl)ethylideneamino)phenyl)‑2‑(5‑methyl‑1H‑pyrazol‑3‑yl) acetamide (L2) have been synthesized and characterized by infrared spectrophotometry (IR), nuclear magnetic resonance spectroscopy (NMR) and electrospray ionization-mass spectrometry (ESI-MS). Two coordination complexes of L1 and L2, namely [Co(L1)(EtOH)]·Cl (1) and [Cu(L2)]·HO (2), respectively have been synthesized and characterized by elemental analysis and spectroscopic studies. The solid state structure of these two complexes was established by single crystal X-ray crystallography. In complex 1, the amide O and pyrazole N atoms of two molecules of L1 take part in coordination with octahedral Co(II) ions, the remaining two coordination sites being occupied by two EtOH molecules leading to a NO coordination environment. On the other hand, the imine N atoms, pyrazole N and O atoms of the 2‑hydroxy‑6‑methyl‑4H‑pyran‑4‑one function present in L2 are involved in coordination with Cu(II) ions, resulting in a distorted square planar geometry displaying a NO chromophore, in complex 2. The crystal packing analysis of 1 and 2, revealed 1D and 2D supramolecular architectures respectively, via various hydrogen bonding interactions, which are discussed in the present account. Furthermore, the antioxidant activity of the ligands and their complexes were determined in vitro by 1,1‑diphenyl‑2‑picrylhydrazyl (DPPH), 2,2'‑azino‑bis(3‑ethylbenzothiazoline‑6‑sulphonic acid (ABTS) and ferric reducing antioxidant power(FRAP), showing that the ligands L1 and L2 and complexes 1 and 2 present significant antioxidant activity.
在本研究中,合成了两种吡唑乙酰胺衍生物,即 N-(2-氨基苯基)-2-(5-甲基-1H-吡唑-3-基)乙酰胺(L1)和(E)-N-(2-(1-(2-羟基-6-甲基-4-氧代-4H-吡喃-3-基)亚乙基氨基)苯基)-2-(5-甲基-1H-吡唑-3-基)乙酰胺(L2),并通过红外光谱(IR)、核磁共振波谱(NMR)和电喷雾电离质谱(ESI-MS)进行了表征。分别合成了 L1 和 L2 的两个配位配合物,即[Co(L1)(EtOH)]·Cl(1)和[Cu(L2)]·HO(2),并通过元素分析和光谱研究进行了表征。通过单晶 X 射线晶体学确定了这两个配合物的固态结构。在配合物 1 中,两个 L1 分子的酰胺 O 和吡唑 N 原子参与配位,形成八面体 Co(II)离子,剩余的两个配位位置由两个 EtOH 分子占据,导致形成 NO 配位环境。另一方面,L2 中的亚胺 N 原子、吡唑 N 和 O 原子与 Cu(II)离子配位,形成扭曲的正方形平面几何形状,呈现出 NO 生色团,在配合物 2 中。通过各种氢键相互作用,1 和 2 的晶体堆积分析分别揭示了 1D 和 2D 超分子结构,在本报告中进行了讨论。此外,通过 1,1-二苯基-2-苦基肼(DPPH)、2,2'-联氮-双(3-乙基苯并噻唑啉-6-磺酸)(ABTS)和铁还原抗氧化能力(FRAP)体外测定了配体及其配合物的抗氧化活性,表明配体 L1 和 L2 以及配合物 1 和 2 具有显著的抗氧化活性。